Treatment of multiple sclerosis with rituximab: A Spanish multicenter experience

INTRODUCTION: Rituximab (RTX) is considered a potential therapeutic option for relapsing-remitting (RRMS) and progressive forms (PMS) of multiple sclerosis (MS). The main objective of this work was to investigate the effectiveness and safety of rituximab in MS. PATIENTS AND METHODS: Observational mu...

Descripción completa

Detalles Bibliográficos
Autores: Gascón-Giménez, Francisco, Alcalá, Carmen, Ramió-Torrentà, Lluís, Montero, Paloma, Matías-Guiu, Jorge, Gómez-Estevez, Irene, Oreja-Guevara, Celia, Gil-Perotín, Sara, Blanco, Yolanda, Carcelen-Gadea, Maria, Quintanilla-Bordás, Carlos, Costa, Lucienne, Villar, Luisa Maria, Martínez-Rodriguez, Jose Enrique, Domínguez, José Andrés, Calles-Hernandez, M. Carmen, González, Inés, Sotoca, Javier, Oterino, Agustin, Lucas-Jimenez, Celia, Pérez-Miralles, Francisco, Casanova, Bonaventura
Tipo de recurso: artículo
Fecha de publicación:2023
País:España
Institución:Conselleria de Salut i Consum del Govern de les Illes Balears
Repositorio:Docusalut
Idioma:inglés
OAI Identifier:oai:docusalut.com:20.500.13003/25433
Acceso en línea:https://hdl.handle.net/20.500.13003/25433
Access Level:acceso abierto
Palabra clave:Antibodies, Monoclonal
Multiple Sclerosis
Multiple Sclerosis, Chronic Progressive
Multiple Sclerosis, Relapsing-Remitting
Rituximab
Anticuerpos Monoclonales
Esclerosis Múltiple
Esclerosis Múltiple Crónica Progresiva
Esclerosis Múltiple Recurrente-Remitente
anti-CD20 monoclonal antibody
multiple sclerosis
progressive multiple sclerosis
relapsing-remitting multiple sclerosis
rituximab
treatment
Descripción
Sumario:INTRODUCTION: Rituximab (RTX) is considered a potential therapeutic option for relapsing-remitting (RRMS) and progressive forms (PMS) of multiple sclerosis (MS). The main objective of this work was to investigate the effectiveness and safety of rituximab in MS. PATIENTS AND METHODS: Observational multicenter study of clinical and radiological effectiveness and safety of rituximab in RRMS and PMS. RESULTS: A total of 479 rituximab-treated patients were included in 12 Spanish centers, 188 RRMS (39.3%) and 291 (60.7%) PMS. Despite standard treatment, the annualized relapse rate (ARR) the year before RTX was 0.63 (: 0.8) and 156 patients (41%) had at least one gadolinium-enhanced lesion (GEL) on baseline MRI. Mean EDSS had increased from 4.3 ( 1.9) to 4.8 (: 1.7) and almost half of the patients (41%) had worsened at least one point. After a median follow-up of 14.2 months ( 6.5-27.2), ARR decreased by 85.7% ( < 0.001) and GEL by 82.9%, from 0.41 to 0.07 ( < 0.001). A significant decrease in EDSS to 4.7 ( = 0.046) was observed after 1 year of treatment and this variable remained stable during the second year of therapy. There was no evidence of disease activity in 68% of patients. Infusion-related symptoms were the most frequent side effect (19.6%) and most were mild. Relevant infections were reported only in 18 patients (including one case of probable progressive multifocal leukoencephalopathy). CONCLUSION: Rituximab could be an effective and safe treatment in RRMS, including aggressive forms of the disease. Some selected PMS patients could also benefit from this treatment.

Similares en LA Referencia